Posted in | News | Optics and Photonics

Precision Biopsy Moves into FRA’s Bioscience 2 Building to Market ClariCore Optical Biopsy System

The Fitzsimons Redevelopment Authority (FRA) announced that Precision Biopsy is the first commercial company moving into their new Bioscience 2 building, which opened in June.

This custom-built space allows Precision Biopsy to expand from the pre-built lab they occupied in Bioscience 1 as the company initiates a global commercialization strategy for its real-time tissue classification technology used in prostate biopsy procedures.

Located adjacent to the Anschutz Medical campus on property that the University of Colorado purchased from the FRA, Bioscience 2 is a new multi-tenant building spanning more than 112,000 square feet that will combine university activities with commercial uses. The facility’s strategic location will foster a unique network between students and industry, while achieving the mission of the FRA and the university to evolve the historic army medical center into one of the world’s most forward-looking bioscience districts.

“We are very excited to be the first company to move into this new facility. This space will allow us to expand our resources to bring our ClariCore Optical Biopsy System™ to market, providing us with the opportunity to potentially help the millions of patients who undergo prostate biopsy procedures each year,” said Amir Tehrani, Chief Executive Officer of Precision Biopsy.

University of Colorado tenants will occupy the first two floors of Bioscience 2 with the University’s Bioengineering program and two other university entities, while the third and fourth floors will be home to FRA commercial organizations.

“Precision Biopsy exemplifies the type of innovative businesses successfully growing in the Fitzsimons Innovation Campus today. We will continue to create an environment that encourages the growth of a wide variety of companies that can thrive and take advantage of the adjacency of the Anschutz Medical Campus and proximity to DIA,” said Steve VanNurden, President & CEO of Fitzsimons Redevelopment Authority.

“The Precision Biopsy ClariCore™ system exemplifies the kind of scientific breakthrough that aims to markedly improve the clinical path and outcome for prostate cancer patients while saving inordinate costs to the healthcare system. I am thrilled to contribute to their tremendous progress,” said Dr. E. David Crawford, Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado, who also serves as Precision Biopsy’s primary investigator. “This is a fine example of industry and academia working closely in collaboration to solve a major issue.”


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type